Video
Author(s):
Key opinion leaders on multiple myeloma reflect on the use of combination strategies with bispecifics in the multiply relapsed setting.
Revisit Every OncLive On Air Episode From May 2024
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Non-Pharmacologic Therapies for Pain Management in Patients With Cancer: Opportunities and Challenges
Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa
First-Line Quadruplet Regimens Continue to Enhance Outcomes in Myeloma
Weighing the Benefits and Limitations of CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
Dr Grünwald on Examining Progression Patterns for Lenvatinib Plus Pembrolizumab in Advanced RCC
Dr Gerds on Updated Data for Pelabresib Plus Ruxolitinib in JAK Inhibitior–Naive Myelofibrosis
Asciminib Bests Standard-of-Care TKIs in Ph+ CML
Lorlatinib Yields Longest Reported PFS in Advanced NSCLC